A prospective, single-arm, multi-center phase IV clinical research to evaluate the safety of Jinhua Qinggan Granules in the treatment of influenza

Phase 4

• Conditions: Influenza

• Registration Number: ITMCTR2100005166
• Lead Sponsor: Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Meet the influenza clinical diagnosis standard of Influenza Diagnosis and Treatment Plan (2020 Edition);
2.The age range of patients is over 18 years old (inclusive);
3.The course of disease was within 48 hours;
4.Agree to participate in this study and sign a written informed consent form.

Exclusion Criteria

1. Severe or critically ill patients with influenza;
2. Patients with abnormal liver function;
3. Abnormal blood routine indexes;
4. The patient has test data reflecting abnormal renal function;
5. Pregnant and lactating patients;
6. Combination of serious primary diseases of the heart, brain, lung, liver, kidney and blood system, such as viral hepatitis, hemophilia, mental illness, etc.;
7. According to the judgment of the researcher, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as pregnancy, frequent changes in working environment, unstable living environment, etc., which are likely to cause loss to follow-up;
8. Other investigators judge that there are patients who affect the safety of the drug.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse reaction rate;Body temperature normalization rate and hypothermia value;Types of adverse reactions;